Variants in interleukin family of cytokines genes influence clearance of high risk HPV in HIV-1 coinfected African-American adolescents

Human Immunology

Volumn 74, Issue 12, 2013, Pages 1696-1700

  Sudenga, Staci L ^a   Wiener, Howard W ^a   Shendre, Aditi ^a   Wilson, Craig M ^a   Tang, Jianming ^b   Shrestha, Sadeep ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 7 RECEPTOR;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ADOLESCENCE; ADOLESCENT; ADULT; AFRICAN AMERICAN; ALLELE; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; EXON; FEMALE; FOLLOW UP; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; MAJOR CLINICAL STUDY; MIXED INFECTION; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; RISK ASSESSMENT; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; VIRAL CLEARANCE; WART VIRUS;

ADOLESCENT; AFRICAN AMERICANS; ALLELES; CHILD; COINFECTION; FEMALE; GENE FREQUENCY; GENOTYPE; HIV INFECTIONS; HUMANS; INTERLEUKINS; PAPILLOMAVIRUS INFECTIONS; POLYMORPHISM, SINGLE NUCLEOTIDE; YOUNG ADULT;

EID: 84888202735     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2013.08.010     Document Type: Article

References (30)

1. Sudenga S.L., Shrestha S. Key considerations and current perspectives of epidemiological studies on human papillomavirus persistence, the intermediate phenotype to cervical cancer. Int J Infect Dis 2013, 17:e216-e220.
2. Rositch A.F., Koshiol J., Hudgens M., Razzaghi H., Backes D.M., Pimenta J.M., et al. Patterns of persistent genital human papillomavirus infection among women worldwide: a literature review and meta-analysis. Int J Cancer 2012, 10.1002/ijc.27828.
3. Wang S.S., Hildesheim A. Viral and host factors in human papillomavirus persistence and progression. J Natl Cancer Inst Monogr 2003, 35-40. [chapter 5].
4. Tindle R.W. Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer 2002, 2:59-65.
5. Palefsky J.M. Cervical human papillomavirus infection and cervical intraepithelial neoplasia in women positive for human immunodeficiency virus in the era of highly active antiretroviral therapy. Curr Opin Oncol 2003, 15:382-388.
6. Ahdieh L., Munoz A., Vlahov D., Trimble C.L., Timpson L.A., Shah K. Cervical neoplasia and repeated positivity of human papillomavirus infection in human immunodeficiency virus-seropositive and -seronegative women. Am J Epidemiol 2000, 151:1148-1157.
7. Sun X.W., Kuhn L., Ellerbrock T.V., Chiasson M.A., Bush T.J., Wright T.C. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 1997, 337:1343-1349.
8. Shrestha S., Sudenga S.L., Smith J.S., Bachmann L.H., Wilson C.M., Kempf M.C. The impact of highly active antiretroviral therapy on prevalence and incidence of cervical human papillomavirus infections in HIV-positive adolescents. BMC Infect Dis 2010, 10:295.
9. Bratcher L.F., Sahasrabuddhe V.V. The impact of antiretroviral therapy on HPV and cervical intraepithelial neoplasia: current evidence and directions for future research. Infect Agent Cancer 2010, 5:8.
10. Wilson C.M., Houser J., Partlow C., Rudy B.J., Futterman D.C., Friedman L.B. The REACH (reaching for excellence in adolescent care and health) project: study design, methods, and population profile. J Adolesc Health 2001, 29:8-18.
11. Moscicki A.B., Ellenberg J.H., Vermund S.H., Holland C.A., Darragh T., Crowley-Nowick P.A., et al. Prevalence of and risks for cervical human papillomavirus infection and squamous intraepithelial lesions in adolescent girls: impact of infection with human immunodeficiency virus. Arch Pediatr Adolesc Med 2000, 154:127-134.
12. Azzato E.M., Greenberg D., Shah M., Blows F., Driver K.E., Caporaso N.E., et al. Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates?. Br J Cancer 2009, 100:1806-1811.
13. Nyholt D.R. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 2004, 74:765-769.
14. Benjamini Y., Krieger A.M., Yekutieli D. Adaptive linear step-up procedures that control the false discovery rate. Biometrika 2006, 93:491-507.
15. Xue X., Gange S.J., Zhong Y., Burk R.D., Massad L.S., et al. Marginal and mixed-effects models in the analysis of human papillomavirus natural history data. Cancer Epidemiol Biomarkers Prev 2010, 19:159-169.
16. Park S.J., Yoon Y.C., Kang S.W., Kim T.H., Kim Y.W., Joo H., et al. Impact of IL2 and IL2RB genetic polymorphisms in kidney transplantation. Transplant Proc 2011, 43:2383-2387.
17. Arend W.P., Malyak M., Guthridge C.J., Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 1998, 16:27-55.
18. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
19. Williams V.M., Filippova M., Soto U., Duerksen-Hughes P.J. HPV-DNA integration and carcinogenesis: putative roles for inflammation and oxidative stress. Future Virol 2011, 6:45-57.
20. Korthagen N.M., van Moorsel C.H., Kazemier K.M., Ruven H.J., Grutters J.C. IL1RN genetic variations and risk of IPF: a meta-analysis and mRNA expression study. Immunogenetics 2012, 64:371-377.
21. Singh H., Sachan R., Goel H., Mittal B. Genetic variants of interleukin-1RN and interleukin-1beta genes and risk of cervical cancer. BJOG 2008, 115:633-638.
22. Mustea A., Sehouli J., Konsgen D., Stengel D., Sofroni D., Lichtenegger W. Interleukin 1 receptor antagonist (IL-1RA) polymorphism in women with cervical cancer. Anticancer Res 2003, 23:1099-1102.
23. Sehouli J., Mustea A., Konsgen D., Katsares I., Lichtenegger W. Polymorphism of IL-1 receptor antagonist gene: role in cancer. Anticancer Res 2002, 22:3421-3424.
24. Sousa H., Santos A.M., Catarino R., Pinto D., Canedo P., et al. IL-1RN VNTR polymorphism and genetic susceptibility to cervical cancer in Portugal. Mol Biol Rep 2012, 39:10837-10842.
25. Tamandani D.M., Sobti R.C., Shekari M., Kaur S., Huria A. Impact of polymorphism in IL-1RA gene on the risk of cervical cancer. Arch Gynecol Obstet 2008, 277:527-533.
26. Van Dyke A.L., Cote M.L., Wenzlaff A.S., Chen W., Land S., et al. Cytokine and cytokine receptor single-nucleotide polymorphisms predict risk for non-small cell lung cancer among women. Cancer Epidemiol Biomarkers Prev 2009, 18:1829-1840.
27. Shrestha S., Wang C., Aissani B., Wilson C.M., Tang J., Kaslow R.A. Interleukin-10 gene (IL10) polymorphisms and human papillomavirus clearance among immunosuppressed adolescents. Cancer Epidemiol Biomarkers Prev 2007, 16:1-7.
28. Safaeian M., Hildesheim A., Gonzalez P., Yu K., Porras C., Li Q., et al. Single nucleotide polymorphisms in the PRDX3 and RPS19 and risk of HPV persistence and cervical precancer/cancer. PLoS One 2012, 7:e33619.
29. Wang S.S., Bratti M.C., Rodriguez A.C., Herrero R., Burk R.D., Porras C., et al. Common variants in immune and DNA repair genes and risk for human papillomavirus persistence and progression to cervical cancer. J Infect Dis 2009, 199:20-30.
30. Wang S.S., Gonzalez P., Yu K., Porras C., Li Q., Safaeian M., et al. Common genetic variants and risk for HPV persistence and progression to cervical cancer. PLoS One 2010, 5:e8667.